Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 2/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24453122 | 1.00 | NQO2 (0.53) | NQO2MTNR1AMTNR1BSPRSNCA | |
| SCHEMBL21614222 | 0.91 | CDK2 (0.49) | NQO2MTNR1AMTNR1BSPRSNCA | |
| SCHEMBL21614219 | 0.87 | MTNR1A (0.54) | NQO2MTNR1AMTNR1BSPRSNCA | |
| SCHEMBL21614209 | 0.86 | MTNR1A (0.53) | NQO2MTNR1AMTNR1BSPRSNCA | |
| SCHEMBL21614215 | 0.86 | SNCA (0.53) | NQO2MTNR1AMTNR1BSPRSNCA | |
| SCHEMBL21614211 | 0.85 | MTNR1A (0.73) | NQO2MTNR1AMTNR1BSPRMEN1 | |
| SCHEMBL21614242 | 0.84 | NQO2 (0.51) | NQO2MTNR1AMTNR1BSPRSNCA | |
| SCHEMBL21614223 | 0.84 | NR4A2 (0.51) | NQO2MTNR1AMTNR1BSPRMEN1 | |
| SCHEMBL14550631 | 0.83 | KMT2A (0.53) | NQO2MTNR1AMTNR1BLMNATP53 | |
| SCHEMBL29655424 | 0.83 | KMT2A (0.53) | NQO2MTNR1AMTNR1BLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240327350-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | NQO2 1718/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | NQO2 1718/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | NQO2 1718/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | NQO2 1718/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
| US-20240327350-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | NQO2 1718/4885MTNR1A 2658/4885MTNR1B 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.